Meanwhile, studies combining multimodal biomarkers (103) (e.g., Aβ-PET, tau-PET, cerebrospinal fluid markers, and genetic markers) will contribute to a more comprehensive understanding of the link between the two and provide new avenues for early identification and monitoring of Alzheimer’s disease. The gene discussed is MAPT; the disease is Alzheimer disease.